Background: Haemophilia is a disease of genetic origin, which causes a defect in blood coagulation. Under normal conditions, in the case of leakage from the blood vessels, the blood forms a clot that reduces or blocks the bleeding. This process involves the activation of several plasma proteins in a cascade-like species. Two of these proteins, produced in the liver, factor VIII and factor IX, are deficient or present a functional defect in people with haemophilia. Because of this deficit, the haemophiliacs easily suffer external and internal bleeding. Surgical treatment of these patients is to be observed, and often their treatment is delayed due to unclear guidelines and risks in treating these patients. The aim is to provide clear guidelines in the case of surgical treatment of these patients.
Methods: In this study, we have considered all the guidelines that refer to the gold-maxillofacial surgery, focusing on the literature of the last 10 years.
Results: Surely, this collection of guidelines will favor the choice of the clinician towards safer and predictable protocols. This study does not want to create a guideline but evaluates the literature of the last 10 years, and highlights the latest for the treatment of these patients., with the aim of informing the pathology and at the same time making the surgical maneuvers safer.
Conclusions: Despite the research of literature has produced few results, it was nevertheless possible to draw up a guideline thanks to additional information extrapolated from textbooks and other scientific articles. According to the guidelines, it is possible to proceed to the treatment of these patients, if with appropriate therapy in a safe and risk-free manner.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518229 | PMC |
http://dx.doi.org/10.3390/ijerph16081386 | DOI Listing |
Nephrol Nurs J
January 2025
Kidney Transplant Coordinator, Atrium Health, Carolinas Medical Center in Charlotte, NC.
Patients in need of a kidney transplant have the option of receiving a kidney from a living donor or a deceased donor. Patients in the United States who do not have an available living donor typically wait on the deceased donor waiting list for an average of three to five years, although some patients may wait longer. The waiting list is very complex and intended to allocate kidneys in a fair and equitable manner.
View Article and Find Full Text PDFNephrol Nurs J
January 2025
Research Associate Professor of Biostatistics, Department of Biostatics and Computational Biology, University of Rochester Medical Center, Rochester, NY.
Whether pediatric dialysis is morally obligatory is an ethical issue. The study's aim was to understand neonatal and pediatric intensive care unit (ICU) nurses' beliefs regarding the ethical use of pediatric dialysis. A single center study was conducted using theoretical and case-based surveys.
View Article and Find Full Text PDFNephrol Nurs J
January 2025
Senior Consultant to the Global Medical Office, Fresenius Medical Care, Waltham, MA.
Patients with acute kidney injury often require dialysis (AKI-D) in the outpatient setting following hospitalization. Management of the patient with AKI-D should focus on preventing further insult to the damaged kidney and recovery of kidney function. Clinical attention should include continuity of care, education, infection control, medication management, and fluid management.
View Article and Find Full Text PDFNephrol Nurs J
January 2025
Director, the Marian K. Shaughnessy Nurse Leadership Academy.
Nephrology nurses working in hemodialysis units face unique challenges managing multiple patients - an experience often contributing to higher levels of burnout and stress, and potentially lower job satisfaction and retention rates, exacerbating the existing nursing shortage in dialysis settings. Targeted strategies are essential to improve job satisfaction. In this study, we explored the relationship between emotional intelligence and job satisfaction among nephrology nurses working in acute and chronic hemodialysis settings.
View Article and Find Full Text PDFHum Gene Ther
January 2025
BridgeBio Gene Therapy, Palo Alto, California, USA.
Complement-mediated thrombotic microangiopathy (TMA) in the form of atypical hemolytic uremic syndrome (aHUS) has emerged as an immune complication of systemic adeno-associated virus (AAV) gene transfer that was unforeseen based on nonclinical studies. Understanding this phenomenon in the clinical setting has been limited by incomplete data and a lack of uniform diagnostic and reporting criteria. While apparently rare based on available information, AAV-associated TMA/aHUS can pose a substantial risk to patients including one published fatality.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!